Key Takeaways
- U.S. President Trump is delaying a $14 billion arms package for Taiwan after discussions with Chinese President Xi Jinping.
- The U.S. House of Representatives has approved $500 million in Foreign Military Financing for Taiwan as part of broader defense support.
- Experts suggest the funding could fulfill older arms deals despite uncertainties surrounding the proposed larger package.
U.S. Arms Approvals for Taiwan in Question
U.S. President Donald Trump remains hesitant to approve a $14 billion arms package for Taiwan, a concern amidst increasing tensions with China. Following a meeting in May with Chinese President Xi Jinping, who opposes U.S. military support for Taiwan, Trump pulled back on the package. However, recent developments indicate that the U.S. Congress is still intent on supporting Taiwan in its defense.
On July 15, the House of Representatives passed a bill including $500 million in Foreign Military Financing (FMF) allocated for Taiwan. This funding, as part of the 2027 fiscal year appropriations bill, does not earmark money for a specific arms deal but signals that the Republican-dominated Congress prioritizes Taiwan’s defense against potential aggression from China. Analysts interpret this as a commitment to uphold prior arms agreements, regardless of the larger package’s uncertain status.
Huang Chung-ting, an associate research fellow at the Institute for National Defense and Security Research in Taipei, remarked, “This $500 million Foreign Military Financing demonstrates that Congress has not reduced its security support for Taiwan following the Trump-Xi meeting.” This move reflects Congress’s intent to maintain military aid to Taiwan without long-term restrictions based on negotiations with China.
Trump’s approval of the appropriations bill is necessary for proceeding with any weapons sales. While the FMF can be directed toward various military acquisitions, it does not guarantee that new arms sales will occur. Sean King, vice president of the political consultancy Park Strategies, stated, “Foreign military financing concerns how weapons are ultimately paid for but not whether the weapons are actually sold or transferred.”
Despite the uncertainty surrounding the larger arms package, analysts note that Trump has not formally retracted any pending arms sales to Taiwan. This leaves the possibility that the congressional funding could support existing, but unfulfilled, sales. As of April, the Taiwan Security Monitor initiative highlighted that several U.S. arms sales, including 30 different weapon types, remain partially unfulfilled.
The most recent approvals consist of a package worth $11.1 billion that includes advanced weaponry such as M109A7 self-propelled howitzers and high mobility artillery rocket systems. Taiwan’s government approved a special budget in May to support these acquisitions.
While the May meeting between Trump and Xi led to a pause in new arms sales, observers believe the delay was influenced by a combination of factors: negotiations with China, a review of U.S. weapon stockpiles, and scrutiny within the Trump administration. The appropriations bill still requires Senate approval before reaching Trump’s desk.
China considers Taiwan to be a breakaway province and has threatened military action if necessary. Throughout the past four years, the People’s Liberation Army has heightened its military drills in proximity to Taiwan, with increasing frequency.
Trump suggested that withholding the arms package could serve as a strategic negotiation tool. However, the State Department has reiterated that U.S. arms sales to Taiwan do not depend on approval from Beijing.
Looking ahead, experts believe that significant announcements regarding the $14 billion arms package may only occur after Trump’s anticipated meeting with Xi in September. Doug Barry of The George Washington University speculated, “It may be that Trump is delaying a public announcement until after Xi’s visit to avoid being the skunk who came to the garden party.” The lack of announcements regarding military support has raised eyebrows and remains a topic of interest in U.S.-China relations.
The content above is a summary. For more details, see the source article.